Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients

Current Medical Research and Opinion

Volumn 29, Issue 4, 2013, Pages 315-323

  Mahabaleshwarkar, Rohan K ^a   Yang, Yi ^a   Datar, Manasi V ^a   Bentley, John P ^a   Strum, Matthew W ^a   Banahan, Benjamin F ^a   Null, Kyle D ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Clopidogrel; Drug; Drug interaction; Elderly; Medicare; Proton pump inhibitors

Indexed keywords

CLOPIDOGREL; PROTON PUMP INHIBITOR;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DUODENUM ULCER; ELDERLY CARE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL REFLUX; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OUTPATIENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REFLUX ESOPHAGITIS; RENAL REPLACEMENT THERAPY; STOMACH ULCER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY BYPASS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE SODIUM; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK; STROKE; TICLOPIDINE;

EID: 84875177610     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.772051     Document Type: Article

References (47)

1. Aschenbrenner DS. Drug watch. Am J Nurs 2006;106:29-31
2. Joseph JJ, Pillai A, Bramley D. Clopidogrel in orthopaedic patients: a review of current practice in Scotland. Thromb J 2007;5:6
3. Top 15 Global Products, 2009, Total Audited Markets. IMS Heath Reports. New Jersey, US: IMS Health, 2009. Available at: http://www.imshealth.com/ deployedfiles/imshealth/Global/Content/StaticFile/Top-Line-Data/ Top%2015%20Global%20Products-2009.pdf [Last accessed 16 February 2012]
4. Gurbel PA, Tantry US, Kereiakes DJ. Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. Drug Healthc Patient Saf 2010;2:233-40
5. Harjai KJ, Shenoy C, Orshaw P, et al. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Circ Cardiovasc Interv 2011;4:162-70
6. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, doubleblind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
7. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7
8. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet 2009;374:989-97
9. Gupta E, Bansal D, Sotos J, et al. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 2010;55:1964-8
10. Ho PM, Maddox TM, Wing L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
11. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy 2010;30:787-96
12. Tsai Y, Wen Y, Huang W, et al. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol 2011;46:39-45
13. Van Boxel OS, Van Oijen MGH, Hagenaars MP, et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010;105:2430-6
14. Yasuda H, Yamada M, Sawada S, et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med 2009;48:1725-30
15. Bhurke SM, Martin BC, Li C, et al. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 2012;32:809-18
16. Clopidogrel (marketed as Plavix) and Omeprazole (marketed as Prilosec)-drug interaction. FDA Safety Information. Washingon, DC: US Food and Drug Administration, 2009. Available at: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm [Last accessed 8 December 2011]
17. Public statement on possible interaction between clopidogrel and proton pump inhibitors. London: European Medicines Agency, 2009. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf [Last accessed 12 April 2012]
18. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17
19. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors. Ann Intern Med 2010;152:337-45
20. Schmidt M, Johansen MB, Robertson DJ, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther 2011;35:165-74
21. Hsiao FY, Mullins CD, Wen YW, et al. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf 2011;20:1043-9
22. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010;153:378-86
23. Tentzeris I, Jarai R, Farhan S, et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost 2010;104:1211-18
24. Rossini R, Capodanno D, Musumeci G, et al. Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis 2011;22:199-205
25. Cardiovascular disease risk factors. Geneva: World Heart Federation. Available at: http://www.world-heart-federation.org/cardiovascular-health/ cardiovascular-disease-risk-factors/[Last accessed 4 December 2011]
26. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003;48:133-43
27. Wynne HA, James OFW. The ageing liver. Age Ageing 1990;19:1-3
28. Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009;54:1293-302
29. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011;171:998-1004
30. Ng FH, Tunggal P, Chu WM. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol 2012;107: 389-96
31. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180:713-18
32. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120:2322-9
33. Sørensen R, Gislason GH, Fosbøl EL, et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 2008;66:875-84
34. Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. JAMA 2011;306:1461-7
35. Kiyota Y, Schneeweiss S, Glynn RJ, et al. The accuracy of Medicare claimsbased diagnosis of acute myocardial infarction: estimating positive predictive value based on review of hospital records. Am Heart J 2004;148:99-104
36. Reker DM, Hamilton BB, Duncan PW, et al. Stroke: Who's counting what? J Rehabil Res Dev 2001;38:281-9
37. Harmsze AM, van Werkum JW, Moral F, et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011;22: 98-102
38. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Method Inform Med 1993;32:382-7
39. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Disp 2004;32:821-7
40. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors and clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009;54:1149-53
41. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-19
42. Neubauer H, Engelhardt A, Kruger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopiodgrel: a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol 2010;56:91-7
43. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantopraole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5
44. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011;89:65-74
45. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010;170: 704-10
46. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50: 105-16
47. Tran M, Tafreshi J, Pai RG. Combination of clopidogrel and proton pump inhibitors: implications for clinicians. J Cardiovasc Pharmacol Ther 2010;15:326-37